The DOI matches its Crossref record; 117 of the 121 references it cites were found in a registry or an index.
Pulmonary drug delivery systems for tuberculosis treatment
Abstract
Tuberculosis (TB) remains a major global health problem as it is the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Conventional treatments fail either because of poor patient compliance to the drug regimen or due to the emergence of multidrug-resistant tuberculosis. The aim of this review is to give an update on the information available on tuberculosis, its pathogenesis and current antitubercular chemotherapies. Direct lung delivery of anti-TB drugs using pulmonary delivery systems is then reviewed since it appears as an interesting strategy to improve first and second line drugs. A particular focus is place on research performed on inhalable dry powder formulations of antitubercular drugs to target alveolar macrophages where the bacteria develop. Numerous studies show that anti-TB drugs can be incorporated into liposomes, microparticles or nanoparticles which can be delivered as dry powders to the deep lungs for instantaneous, targeted and/or controlled release. Treatments of infected animals show a significant reduction of the number of viable bacteria as well as a decrease in tissue damage. These new formulations appear as interesting alternatives to deliver directly drugs to the lungs and favor efficient TB treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, the parenteral and pulmonary routes have higher bioavailability due to bypassing the first-pass metabolism.196”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [196]
In the citing paper
“Furthermore, the nanodrug delivery system reduces the adverse systemic side effects and frequency of drug administration, which eventually leads to better patient compliance.196,197”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [196]
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Aerosol Technology Properties, Behavior, and Measurement of Airborne Particles
Laucks, M. L. (2000) · Journal of Aerosol Science · doi:10.1016/s0021-8502(99)00571-6 · Cited by 3,426
Blumberg, H. M., Burman, W. J., Chaisson, R. E., Daley, C. L., Etkind, S. C., Friedman, L. N., Fujiwara, P., Grzemska, M., Hopewell, P. C., Iseman, M. D., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,936
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,524
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J. S., Caponetti, G., Hrkach, J. S., Ben-Jebria, A., Eskew, M. L., Mintzes, J. D., Deaver, D. R., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,184
Deposition of particles in the human respiratory tract in the size range 0.005–15 μm
Heyder, J., Gebhart, J., Rudolf, G., Schiller-Scotland, C. F., & STAHLHOFEN, W. (1986) · Journal of Aerosol Science · doi:10.1016/0021-8502(86)90035-2 · Cited by 1,034
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Turner, P. V., Brabb, T., Pekow, C. A., & Vasbinder, M. A. (2011) · PubMed Central · Cited by 982
Tuberculosis: Pathogenesis, Protection and Control
(1996) · Nature Medicine · doi:10.1038/nm0296-244b · Cited by 977
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Research works printed but not linked: 2
- Kundawala, 2012, Treating tuberculosis with chitosan microparticles loaded with rifampicin as respirable powder for pulmonary delivery Indian, J. Novel Drug Deliv., 4, 57
- Garcia-Contreras, 2007, Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model, Antimicrob. Agents Chemother., 51, 2830, 10.1128/AAC.01164-06 · DOI
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 566
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., Santis, F. D., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 308
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188
Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications
Le, N. T. T., Cao, V. D., Nguyen, T. N. Q., Le, T. T. H., Tran, T. T., & Thi, T. T. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194706 · Cited by 180
Metadata
- Authors
- Pham, D.-D., Fattal, E., & Tsapis, N.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pham, Dinh-Duy
- Tsapis, Nicolas
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 478
- Issue
- 2
- Pages
- 517-529
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W2076894650
- Cited by
- 185
- References
- 121
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 11 · 2023: 23 · 2022: 15 · 2021: 12 · 2020: 26 · 2019: 25 · 2018: 16 · 2017: 14 · 2016: 18 · 2015: 9
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- ANR (ANR-10-LABX-33)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- pulmonary drug delivery, tuberculosis, antitubercular agents, dry powder inhaler, liposomes, microparticles, nanoparticles, alveolar macrophages, multidrug-resistant tuberculosis, medication adherence, controlled drug release, targeted drug delivery
- MeSH terms
- Administration, Inhalation, Animals, Antitubercular Agents, Humans, Powders, Tuberculosis, Pulmonary, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
